Sanofi Cost of Goods Sold 2010-2024 | SNY
Sanofi annual/quarterly cost of goods sold history and growth rate from 2010 to 2024. Cost of goods sold can be defined as the difference between beginning and ending inventories for tangible products resulting in an expense that reflects production and sales costs.
- Sanofi cost of goods sold for the quarter ending September 30, 2024 was $4.492B, a 7.45% increase year-over-year.
- Sanofi cost of goods sold for the twelve months ending September 30, 2024 was $16.256B, a 8.89% increase year-over-year.
- Sanofi annual cost of goods sold for 2023 was $15.408B, a 6.78% increase from 2022.
- Sanofi annual cost of goods sold for 2022 was $14.429B, a 0.48% decline from 2021.
- Sanofi annual cost of goods sold for 2021 was $14.499B, a 4.41% increase from 2020.
Sanofi Annual Cost of Goods Sold
(Millions of US $) |
| 2023 |
$15,408 |
| 2022 |
$14,429 |
| 2021 |
$14,499 |
| 2020 |
$13,887 |
| 2019 |
$13,413 |
| 2018 |
$13,505 |
| 2017 |
$13,124 |
| 2016 |
$11,843 |
| 2015 |
$12,124 |
| 2014 |
$14,661 |
| 2013 |
$14,598 |
| 2012 |
$14,299 |
| 2011 |
$15,184 |
| 2010 |
$11,575 |
| 2009 |
$10,989 |
Sanofi Quarterly Cost of Goods Sold
(Millions of US $) |
| 2024-09-30 |
$4,492 |
| 2024-06-30 |
$3,672 |
| 2024-03-31 |
$3,734 |
| 2023-12-31 |
$4,359 |
| 2023-09-30 |
$4,181 |
| 2023-06-30 |
$3,563 |
| 2023-03-31 |
$3,305 |
| 2022-12-31 |
$3,880 |
| 2022-09-30 |
$3,859 |
| 2022-06-30 |
$3,459 |
| 2022-03-31 |
$3,232 |
| 2021-09-30 |
$3,818 |
| 2021-06-30 |
|
| 2021-03-31 |
$3,236 |
| 2020-09-30 |
$3,712 |
| 2020-03-31 |
$3,161 |
| 2019-09-30 |
$3,485 |
| 2019-03-31 |
$2,974 |
| 2018-03-31 |
$3,128 |
| 2017-12-31 |
$3,629 |
| 2017-09-30 |
$3,353 |
| 2017-06-30 |
$3,174 |
| 2017-03-31 |
$2,968 |
| 2016-12-31 |
$3,195 |
| 2016-09-30 |
$3,098 |
| 2016-06-30 |
$2,850 |
| 2016-03-31 |
$2,700 |
| 2015-09-30 |
$3,336 |
| 2015-06-30 |
$3,250 |
| 2014-06-30 |
$3,578 |
| 2013-06-30 |
$3,493 |
| 2012-06-30 |
$3,512 |
| 2012-03-31 |
$3,444 |
| 2011-12-31 |
$3,753 |
| 2011-09-30 |
$4,099 |
| 2011-06-30 |
$4,101 |
| 2011-03-31 |
$3,232 |
| 2010-12-31 |
$3,152 |
| 2010-09-30 |
$2,962 |
| 2010-06-30 |
$2,647 |
| 2010-03-31 |
$2,814 |
| 2009-12-31 |
$3,098 |
| 2009-09-30 |
$2,898 |
| 2009-06-30 |
$2,523 |
| 2009-03-31 |
$2,471 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$121.816B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
